On Nov 06, major Wall Street analysts update their ratings for $Inspire Medical Systems (INSP.US)$, with price targets ranging from $200 to $270.
Mizuho Securities analyst Anthony Petrone maintains with a buy rating.
Oppenheimer analyst Suraj Kalia maintains with a hold rating.
Stifel analyst Jonathan Block maintains with a hold rating, and adjusts the target price from $170 to $200.
Truist Financial analyst Richard Newitter maintains with a buy rating, and maintains the target price at $250.
Lake Street analyst Frank Takkinen maintains with a buy rating, and maintains the target price at $270.
Furthermore, according to the comprehensive report, the opinions of $Inspire Medical Systems (INSP.US)$'s main analysts recently are as follows:
The analyst noted that Inspire Medical remains a top-tier selection following the company's recent financial performance, which included a significant revenue increase, positive operating margin, and a reaffirmation of future revenue growth projections for its CNS segment.
Inspire Medical's third-quarter sales and earnings per share surpassed Street forecasts, and guidance for 2024 sales and earnings was increased. The outlook for fourth-quarter sales is somewhat softer, attributed to challenges such as hurricane impacts and intravenous shortage headwinds.
Here are the latest investment ratings and price targets for $Inspire Medical Systems (INSP.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
